Therapeutic combination of PI3K inhibitor and a BTK inhibitor

US10328080B2 · kind B2 · utility

Assignee

• Acerta Pharma B.V. · NL

Inventors

• Ahmed Hamdy · Santa Cruz, US
• Wayne Rothbaum · New York, US
• Raquel Izumi · Redwood City, US
• Brian Lannutti · Solana Beach, US
• Todd Covey · Redwood City, US
• Roger Ulrich · Köniz, CH
• Dave Johnson · Capitola, US
• Tjeerd Barf · Ravenstein, NL
• Allard Kaptein · Zaltbommel, NL

Key dates

• Filing date: Dec 5, 2014
• Grant date: Jun 25, 2019
• Expiry date: Dec 5, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-δ inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.